Granules India Limited has informed the Exchange regarding Outcome of Board Meeting held on April 29, 2026.
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Standalone revenue from operations rose to Rs. 34,739.6 million (vs Rs. 30,301.6 million in FY25), with profit for the year at Rs. 4,006.7 million (vs Rs. 3,193.4 million), a ~25.5% jump in net profit and EPS of Rs. 16.48. Consolidated revenue grew to Rs. 53,656.4 million (vs Rs. 44,816.1 million) and consolidated profit rose to Rs. 5,950.2 million (vs Rs. 5,015.2 million), with EPS of Rs. 24.47. A final dividend of Rs. 1.75 per share (175% on face value of Re. 1) was recommended with record date July 30, 2026. Key events during the year included the Gagillapur USFDA warning letter, acquisition of Senn Chemicals AG (Switzerland), and a new German subsidiary and Canadian subsidiary. The company also raised Rs. 3,656.25 million via warrants issued at Rs. 585/warrant. The auditor (S.R. Batliboi & Associates LLP) issued an unqualified, clean opinion with no qualifications or going-concern flags.
Strong year for shareholders with ~25% standalone PAT growth, healthy margins, and a robust 175% dividend — generally positive for sentiment, though the Gagillapur USFDA warning letter remains a regulatory overhang to watch.